Literature DB >> 32779847

Transverse leukonychia (Mees' lines) nail alterations in a COVID-19 patient.

Diego Fernandez-Nieto1, Juan Jimenez-Cauhe1, Daniel Ortega-Quijano1, Borja Diaz-Guimaraens1, Miguel Dominguez-Santas1, Jesus Martinez-Rubio1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32779847      PMCID: PMC7323062          DOI: 10.1111/dth.13863

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   3.858


× No keyword cloud information.
Dear Editor, The coronavirus disease 2019 (COVID‐19) has been associated to a wide variety of skin manifestations, including maculopapular, vesicular, urticarial, livedoid/necrotic and chilblain‐like acral lesions. However, there are no previous reports about nail alterations in COVID‐19 patients. A previously healthy 47‐year‐old Spanish male presented to our clinic with asymptomatic nail changes. Forty‐five days before, he had been admitted to the hospital with mild COVID‐19 bilateral pneumonia, confirmed with a positive polymerase chain reaction (PCR) nasopharyngeal swab, and treated with lopinavir/ritonavir 100 mg/400 mg bid for 10 days with a good response and no need for supplemental oxygen therapy. Laboratory findings during his admission were unremarkable, except for mild lymphopenia (830 cells/μL, range 1000‐4500 cells/μL) and a slight elevation of d‐dimer (1330 ng/mL, range 0‐500 ng/mL). During his stay, he noticed the appearance of transverse, nonblanchable white lines on all of his fingernails. These lines did progressively migrate with the growth of the nail and still persisted at the time of the visit (Figure 1). The described findings were compatible with a diagnosis of Mees' lines.
FIGURE 1

Clinical presentation 45 days after admission due to COVID‐19 pneumonia. Transverse, nonblanchable white lines on the fingernails

Clinical presentation 45 days after admission due to COVID‐19 pneumonia. Transverse, nonblanchable white lines on the fingernails Mees' lines, or transverse leukonychia, are a subtype of true leukonychia that were first described by Mees in 1919 secondary to arsenic intoxication. They have also been associated to other systemic conditions, including heart failure, infectious diseases (leprosy, tuberculosis, malaria, herpes zoster), Hodgkin lymphoma, and the use of chemotherapeutic agents. , , Some authors reserve the name of Mees' lines only for arsenic intoxication, while others use Mees' lines or transverse leukonychia indistinctly. They are thought to be caused by an abnormal keratinization of the nail plate, due to a temporary dysfunction of the nail growth induced by systemic disorders. Mees' lines disappear after the causative agent has ceased. They can be clinically confused with Muehrcke lines, which represent an abnormality of the nail bed vascularization, usually associated to hypoalbuminemia. Therefore, Muehrcke lines are blanchable lines that do not move with nail growth. This is the first report of nail alterations in a COVID‐19‐positive patient. We hypothesize that the COVID‐19 induced a transitory matrix injury, resulting in Mees' lines, as it has been previously described in other systemic conditions. Given the current incidence rate of COVID‐19, and the wide variety of skin manifestations in these patients, we believe that nail alterations like the current case are probably underreported.

CONFLICT OF INTEREST

The authors declare no conflict of interest.
  9 in total

1.  Transverse leukonychia (Mees' lines) associated with docetaxel.

Authors:  Ali Murat Ceyhan; Mehmet Yildirim; Haci Ahmet Bircan; Duygu Zorlu Karayigit
Journal:  J Dermatol       Date:  2010-02       Impact factor: 4.005

2.  Arsenic poisoning and Mees' lines.

Authors:  S Sharma; A Gupta; A Deshmukh; V Puri
Journal:  QJM       Date:  2016-06-01

3.  Mees' lines because of chemotherapy for Hodgkin's lymphoma.

Authors:  Vincenzo Piccolo; Paola Corneli; Iris Zalaudek; Giuseppe Argenziano; Claudio Conforti; Roberto Alfano; Teresa Russo
Journal:  Int J Dermatol       Date:  2019-09-30       Impact factor: 2.736

4.  Urticarial exanthem as early diagnostic clue for COVID-19 infection.

Authors:  Lucía Quintana-Castanedo; Marta Feito-Rodríguez; Iván Valero-López; Clara Chiloeches-Fernández; Elena Sendagorta-Cudós; Pedro Herranz-Pinto
Journal:  JAAD Case Rep       Date:  2020-04-29

5.  Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients.

Authors:  Angelo Valerio Marzano; Giovanni Genovese; Gabriella Fabbrocini; Paolo Pigatto; Giuseppe Monfrecola; Bianca Maria Piraccini; Stefano Veraldi; Pietro Rubegni; Marco Cusini; Valentina Caputo; Franco Rongioletti; Emilio Berti; Piergiacomo Calzavara-Pinton
Journal:  J Am Acad Dermatol       Date:  2020-04-16       Impact factor: 11.527

6.  Muehrcke's lines.

Authors:  Nuno Teixeira Tavares; Andreia Costa; Margarida Damasceno
Journal:  Autops Case Rep       Date:  2018-03-02

7.  Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases.

Authors:  C Galván Casas; A Català; G Carretero Hernández; P Rodríguez-Jiménez; D Fernández-Nieto; A Rodríguez-Villa Lario; I Navarro Fernández; R Ruiz-Villaverde; D Falkenhain-López; M Llamas Velasco; J García-Gavín; O Baniandrés; C González-Cruz; V Morillas-Lahuerta; X Cubiró; I Figueras Nart; G Selda-Enriquez; J Romaní; X Fustà-Novell; A Melian-Olivera; M Roncero Riesco; P Burgos-Blasco; J Sola Ortigosa; M Feito Rodriguez; I García-Doval
Journal:  Br J Dermatol       Date:  2020-06-10       Impact factor: 11.113

8.  Characterization of acute acral skin lesions in nonhospitalized patients: A case series of 132 patients during the COVID-19 outbreak.

Authors:  Diego Fernandez-Nieto; Juan Jimenez-Cauhe; Ana Suarez-Valle; Oscar M Moreno-Arrones; David Saceda-Corralo; Arantxa Arana-Raja; Daniel Ortega-Quijano
Journal:  J Am Acad Dermatol       Date:  2020-04-24       Impact factor: 11.527

9.  Vascular skin symptoms in COVID-19: a French observational study.

Authors:  J D Bouaziz; T A Duong; M Jachiet; C Velter; P Lestang; C Cassius; A Arsouze; E Domergue Than Trong; M Bagot; E Begon; L Sulimovic; M Rybojad
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-20       Impact factor: 9.228

  9 in total
  8 in total

Review 1.  Nails and COVID-19 - A comprehensive review of clinical findings and treatment.

Authors:  Uwe Wollina; Jean Kanitakis; Robert Baran
Journal:  Dermatol Ther       Date:  2021-08-22       Impact factor: 3.858

2.  Transverse orange nail lesions following SARS-CoV-2 infection.

Authors:  Antonella Tammaro; Ganiyat Adenike Ralitsa Adebanjo; Hans-Peter Erasmus; Camilla Chello; Aldo Pezzuto; Sergio Ramirez-Estrada; Jordi Rello
Journal:  Dermatol Ther       Date:  2020-12-22       Impact factor: 3.858

3.  Half and half nail, is it a marker of severe COVID-19 infection?

Authors:  Soraya Aouali; Saida Sefraoui; Nada Zizi; Siham Dikhaye
Journal:  Ann Med Surg (Lond)       Date:  2021-10-16

4.  Evaluation of Nail Findings in Patients with COVID-19 History and Wood's Lamp Examination.

Authors:  Irem Yanatma; Hulya Cenk
Journal:  Skin Appendage Disord       Date:  2021-10-12

Review 5.  Skin disorders associated with the COVID-19 pandemic: A review.

Authors:  Jennifer Akl; Jessica El-Kehdy; Antoine Salloum; Anthony Benedetto; Paula Karam
Journal:  J Cosmet Dermatol       Date:  2021-07-01       Impact factor: 2.189

Review 6.  A review of nail findings associated with COVID-19 infection.

Authors:  E Hadeler; B W Morrison; A Tosti
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-12       Impact factor: 9.228

Review 7.  Leukonychia: What Can White Nails Tell Us?

Authors:  Matilde Iorizzo; Michela Starace; Marcel C Pasch
Journal:  Am J Clin Dermatol       Date:  2022-02-02       Impact factor: 7.403

8.  Patient Recovery from COVID-19 Infections: Follow-Up of Hair, Nail, and Cutaneous Manifestations.

Authors:  Rattapon Thuangtong; Nasikarn Angkasekwinai; Charussri Leeyaphan; Daranporn Triwongwaranat; Kanchalit Thanomkitti; Kanyalak Munprom; Kanokvalai Kulthanan
Journal:  Biomed Res Int       Date:  2021-06-19       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.